期刊文献+

乳腺癌新辅助化疗前后动态增强MRI半定量 被引量:10

Breast Cancer with Neoadjuvant Chemotherapy:Alteration of Dynamic Enhancement-MRI Semi-quantitative Parameters
下载PDF
导出
摘要 目的:用动态增强MRI半定量法研究乳腺癌新辅助化疗前后血流动力学的变化特点。方法:新辅助化疗的26例乳腺癌患者(女性,平均55.2岁)纳入研究,化疗前后采用同一方案进行乳腺动态MRI增强扫描,使用1.5T超导MRI成像仪、3D FSE序列(TR/TE:5.4ms/2.8ms;FOV:34cm;层厚:3mm;间隔:0mm),速度3ml/s团注钆喷葡胺0.2mmol/kg;在工作站上完成血流半定量测定,并对化疗前后结果进行比较。结果:化疗前早期强化参数Efirst、Vfirst、Ee和Ve的均值大于化疗后的残留病灶(P<0.05),化疗前Emax、Vmax和Slopemax的均值大于化疗后残留病灶的均值,化疗前Tmax均值小于化疗后均值(P<0.05),化疗前Ewash和Vwash值高于化疗后的残留病灶(P<0.05)。结论:乳腺癌新辅助化疗前后动态增强MRI半定量研究显示残留病变血流动力学明显下降,血流速率显著减小。 Purpose: To explore alteration of characteristics in dynamic enhancement - MRI( DCE - MRI) semi - quantitative parameters. Methods: Twenty - six patients with surgically and pathologically proven breast carcinoma who had undergone breast DCE - MRI examation before and after neoadjuvant chemotherapy(NAC) were enrolled in our study. Three - dimensional fast spin echo images (3D - FSE) (TR/TE 5.4/2.8ms; FOV 34cm; Slice thickness 3.0ram; Gap 0ram) were acquired on a 1.5T MR system after administration of a bolus injection of 0.2mmol/kg gadopentetate dimeglumine . The semi - quantitative parameters of DCE - MRI were calculated on workstation and compared before and after NAC. Results: The semi - quantitative parameters had significant alteration before and after NAC, that were as followed: The mean value of Efirst, Vfirst, Ee, Ve, Emax, Vmax, Slopemax, Ewash, Vwash after chemotherapy were lower than those values before chemotherapy(P 〈 0.05), Tmax was significant higher than that before chemotherapy(P 〈 0.05) . Conclusion: The mean value of semi - quantitative parameters had significant alteration in a reduced speed and decreased blood flow before and after NAC.
出处 《中国医学计算机成像杂志》 CSCD 北大核心 2011年第3期226-229,共4页 Chinese Computed Medical Imaging
关键词 乳腺肿瘤 新辅助化疗 磁共振成像 Breast neoplasms Neoadjuvant chemotherapy Magnetic resonance imaging
  • 相关文献

参考文献9

  • 1Von MG,Costa SD,Eiermonn W,et al.Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and Docetaxel.J Clin Oncol,1999,17:1999-2005.
  • 2王丽,翟仁友,蒋涛,刘小娟,刘晖,王跃,赵宏颖.乳腺疾病动态增强MRI半定量参数与微血管密度的相关性[J].中国医学影像技术,2007,23(3):388-392. 被引量:22
  • 3Bonadonna G,Valagussa P,Brambilla C,et al.Primary chemother-apy in operable breast cancer:eight-year experience at the Milan Cancer Institute.J Clin Oncol,1998,16:93-100.
  • 4Toj M.Tumor angiogenesis in breast cancer.its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.Breast Cancer Res Treat,1995,36:193-204.
  • 5Kuhl CK,Mideareck P,Klaschik S,et al.Dynamic breast MR imaging:Aresignal intensity time course data useful for differential diagnosis of enhancing lesions.Radiology,1999,211:101-110.
  • 6张国淳,王深明,吴惠茜.新辅助化疗对乳腺癌细胞增殖微血管密度和组织学分级的影响[J].中国实用外科杂志,2003,23(10):617-619. 被引量:5
  • 7Rieber A,Brambs HJ,Gabelmann A,et al.Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy.Eur Radiol,2002,12:1711-1719.
  • 8Yu HJ,Chen JH,Mehta RS,et al.MRI Measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.J Magn Reson Imaging,2007,26:615-623.
  • 9Wasser K,Klein SK,Fink C,et al.Evaluation of neoadjuvant chemothe-rapeutic response of breast cancer using dynamic MRI with high temporal resolution.Eur Radiol,2003,13:80-87.

二级参考文献23

  • 1陈蓉,龚水根,张伟国,陈金华,何双梧,刘宝华,李增鹏.乳腺肿瘤动态增强MRI对比剂空间分布及其与微血管密度的相关性研究[J].临床放射学杂志,2004,23(10):857-861. 被引量:17
  • 2De Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology, 2000,36 (4) : 306-312.
  • 3Elston CW, Ellis IO. Pathological prognostic faetors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long - term follow - up. Histopathology,1991,19(5) :403 - 410.
  • 4Scholl SM. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.Eur J Cancer, 1994,30A(5) :645.
  • 5Vlastos G. The feasibility of minimally invasive surgery for stage Ⅱ a,Ⅱ b, and Ⅲ a breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer,2000,88(6) : 1417.
  • 6Cleator SM, Parton M, Dowsett. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer,2002,9(3) ;183.
  • 7Smith IC. Neoadjuvant chemotherapy in breast cancer., significantly enhanced response with docetaxel. J Clin Oncol, 2002,20 (6) : 1456.
  • 8Baltali E. Neoadjuvant chemotherapy with taxotere - epirubicin - 5- fluorouracil (TEF) in local- regionally advanced breast cancer:a preliminary report. Tumor,2002,88(6) :474.
  • 9Kelman Z. PCNA: structure, functions and interactions. Oncogene,1997,14:629.
  • 10Toi M. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat, 1995,36 (2) :193.

共引文献24

同被引文献67

引证文献10

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部